tiprankstipranks
Advertisement
Advertisement

CAPR Stock Latest News

Capricor Faces FDA Advisory Review for DMD Therapy
Company AnnouncementsCapricor Faces FDA Advisory Review for DMD Therapy
14d ago
8K
CAPR
Midday Fly By: On Semi to acquire Synaptics, OpenAI leans toward 2027 IPO
PremiumThe Fly
Midday Fly By: On Semi to acquire Synaptics, OpenAI leans toward 2027 IPO
15d ago
BA
GS
Capricor announces FDA advisory committee meeting to review Deramiocel BLA
PremiumThe Fly
Capricor announces FDA advisory committee meeting to review Deramiocel BLA
15d ago
CAPR
Capricor presents five-year data from HOPE-2 open-label extension study
PremiumThe Fly
Capricor presents five-year data from HOPE-2 open-label extension study
15d ago
CAPR
Capricor Therapeutics management to meet with Oppenheimer
PremiumThe Fly
Capricor Therapeutics management to meet with Oppenheimer
25d ago
CAPR
Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot
PremiumCompany AnnouncementsCapricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot
2M ago
CAPR
CAPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
CAPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
CAPR
Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy
Premium
Company Announcements
Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy
2M ago
CAPR
Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital
PremiumThe Fly
Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital
2M ago
CAPR
Analyst Reiterates Buy on Capricor Ahead of Key 2026 PDUFA, Maintains $60 Price Target
PremiumRatings
Analyst Reiterates Buy on Capricor Ahead of Key 2026 PDUFA, Maintains $60 Price Target
2M ago
CAPR
FDA Commissioner Marty Makary resigns
PremiumThe Fly
FDA Commissioner Marty Makary resigns
2M ago
AZN
BMY
Capricor Therapeutics options imply 9.4% move in share price post-earnings
PremiumThe Fly
Capricor Therapeutics options imply 9.4% move in share price post-earnings
2M ago
CAPR
Capricor Buy Rating Reiterated on Deramiocel Opportunity and NS Pharma Dispute Dynamics; $50 Price Target Maintained
PremiumRatingsCapricor Buy Rating Reiterated on Deramiocel Opportunity and NS Pharma Dispute Dynamics; $50 Price Target Maintained
2M ago
CAPR
Capricor files suit against NS Pharma over Deramiocel distribution deal
Premium
The Fly
Capricor files suit against NS Pharma over Deramiocel distribution deal
2M ago
CAPR
Capricor Sues NS Pharma Over Deramiocel U.S. Rights
Premium
Company Announcements
Capricor Sues NS Pharma Over Deramiocel U.S. Rights
2M ago
8K
CAPR
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 3/30/26, According to Analysts
PremiumMarket News
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 3/30/26, According to Analysts
3M ago
XEL
CAPR
Capricor Therapeutics price target raised to $43 from $41 at Roth Capital
PremiumThe Fly
Capricor Therapeutics price target raised to $43 from $41 at Roth Capital
4M ago
CAPR
Capricor Therapeutics Nears Key Milestones After Earnings Call
PremiumCompany Announcements
Capricor Therapeutics Nears Key Milestones After Earnings Call
4M ago
CAPR
Capricor selloff today a buying opportunity, says Roth Capital
PremiumThe Fly
Capricor selloff today a buying opportunity, says Roth Capital
4M ago
CAPR
Capricor Therapeutics price target raised to $51 from $48 at Alliance Global
PremiumThe FlyCapricor Therapeutics price target raised to $51 from $48 at Alliance Global
4M ago
CAPR
Capricor Therapeutics price target raised to $63 from $50 at B. Riley
Premium
The Fly
Capricor Therapeutics price target raised to $63 from $50 at B. Riley
4M ago
CAPR
Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler
Premium
The Fly
Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler
4M ago
CAPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >